In a boost to Rit­ux­an fran­chise, Roche nabs quick ap­proval for po­latuzum­ab ve­dotin

6 years ago
Pharma

FDA sends No­vaVax back to the clin­ic; Stoke Ther­a­peu­tics sets terms for up­sized $101M IPO

6 years ago
News Briefing

Lil­ly's Trulic­i­ty CV out­comes da­ta un­der­whelm amid block­buster di­a­betes ri­val­ry with No­vo

6 years ago
Pharma

Bat­tered by le­gal ex­pens­es, opi­oid drug­mak­er In­sys files for bank­rupt­cy days af­ter $225M deal to set­tle gov­ern­ment ...

6 years ago

Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

6 years ago
Startups

Ar­ti­zan com­pletes mi­cro­bio­me starter pack­age with Brii deal, CSO hire and some mon­ey to dash for the clin­ic

6 years ago
Financing
Startups

Mer­ck makes a $773M bet on TGFβ, ac­quir­ing a three-year-old biotech

6 years ago
Deals

'We kept at it': Jef­frey Blue­stone plots late-stage come­back af­ter teplizum­ab shown to de­lay type 1 di­a­betes

6 years ago
R&D

Aptinyx's lead drug makes cut in small fi­bromyal­gia tri­al, set­ting the stage for larg­er chron­ic pain study

6 years ago
R&D

In­vestors fret as new reg­u­la­to­ry probes spur fresh de­lays to Roche's $4.3B Spark buy­out

6 years ago
Deals

Han­soh grabs $1B wind­fall in the lat­est Chi­na phar­ma IPO to hit the Hong Kong ex­change

6 years ago
Financing
China

Ot­su­ka scores PhI­II win for an­oth­er As­tex drug; GSK ex­pands Nu­cala use in asth­ma

6 years ago
News Briefing

La Jol­la whips up some love for iron over­load drug with promis­ing da­ta snap­shot

6 years ago
R&D

Lab­Corp se­lects its new CEO; Pfiz­er names ex-Genen­tech vet as new head of on­col­o­gy R&D

6 years ago
Peer Review

CDER drafts drug de­vel­op­ment guid­ance on NASH with com­pen­sat­ed cir­rho­sis

6 years ago
FDA+

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

6 years ago
Pharma

Once picked as a $500M win­ner, bank­rupt Achao­gen auc­tions off its an­tibi­ot­ic for a frac­tion of that

6 years ago
Pharma

Sanofi re­cruits No­var­tis' top phar­ma ex­ec Paul Hud­son as its new CEO — so what hap­pens now?

6 years ago
People

R&D leader Ver­tex ex­e­cutes a $420M cash gam­bit to dom­i­nate gene edit­ing field for Duchenne MD

6 years ago
Deals
Cell/Gene Tx

Ex-Juno chief Hans Bish­op takes the helm at can­cer test­ing start­up Grail in a shake­up as IPO ru­mors per­co­late

6 years ago
People

Vivek Ra­maswamy re­cruits Eli Lil­ly R&D vet Salz­mann as new CEO; Ax­o­vant drops col­lab­o­ra­tion

6 years ago
News Briefing

Pro­tal­ix, Chiesi fire up ac­cel­er­at­ed ap­proval pitch for Fab­ry dis­ease treat­ment

6 years ago
R&D

Fi­nan­cial­ly wob­bly opi­oid drug­mak­er In­sys agrees to pay $225M to set­tle gov­ern­ment probes

6 years ago
Pharma

Cel­gene can breathe a sigh of re­lief as FDA ac­cepts once-spurned ozan­i­mod ap­pli­ca­tion — set­ting a tar­get date on a ...

6 years ago
Pharma
First page Previous page 927928929930931932933 Next page Last page
A service from the Financial Times